30175133|t|Serum Lipidomics Profiling to Identify Biomarkers for Non-Small Cell Lung Cancer.
30175133|a|Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide, which ranks top in both incidence and mortality. To broaden our understanding of the lipid metabolic alterations in NSCLC and to identify potential biomarkers for early diagnosis, we performed nontargeted lipidomics analysis in serum from 66 early-stage NSCLC, 40 lung benign disease patients (LBD), and 40 healthy controls (HC) using Ultrahigh Performance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry (UHPLC-Q-TOF/MS). The identified biomarker candidates of phosphatidylcholines (PCs) and phosphatidylethanolamines (PEs) were further externally validated in a cohort including 30 early-stage NSCLC, 30 LBD, and 30 HC by a targeted lipidomic analysis. We observed a significantly altered lipid metabolic profile in early-stage NSCLC and identified panels of PCs and PEs to distinguish NSCLC patients and HC. The levels of PCs and PEs were found to be dysregulated in glycerophospholipid metabolism, which was the top altered pathway in early-stage NSCLC. Receiver operating characteristic (ROC) curve analysis revealed that panels of PCs and PEs exhibited good performance in differentiating early-stage NSCLC and HC. The levels of PE(16:0/16:1), PE(16:0/18:3), PE(16:0/18:2), PE(18:0/16:0), PE(17:0/18:2), PE(18:0/17:1), PE(17:0/18:1), PE(20:5/16:0), PE(18:0/18:1), PE(18:1/20:4), PE(18:0/20:3), PC(15:0/18:1), PC(16:1/20:5), and PC(18:0/20:1) in early-stage NSCLC were significantly increased compared with HC (p<0.05). Overall, our study has thus highlighted the power of using comprehensive lipidomic approaches to identify biomarkers and underlying mechanisms in NSCLC.
30175133	54	80	Non-Small Cell Lung Cancer	Disease	MESH:D002289
30175133	82	108	Non-small cell lung cancer	Disease	MESH:D002289
30175133	110	115	NSCLC	Disease	MESH:D002289
30175133	141	153	cancer death	Disease	MESH:D009369
30175133	250	255	lipid	Chemical	MESH:D008055
30175133	281	286	NSCLC	Disease	MESH:D002289
30175133	419	424	NSCLC	Disease	MESH:D002289
30175133	429	448	lung benign disease	Disease	MESH:D008171
30175133	449	457	patients	Species	9606
30175133	459	462	LBD	Species	
30175133	645	665	phosphatidylcholines	Chemical	MESH:D010713
30175133	667	670	PCs	Chemical	MESH:D010713
30175133	676	701	phosphatidylethanolamines	Chemical	MESH:D010714
30175133	703	706	PEs	Chemical	MESH:D010714
30175133	779	784	NSCLC	Disease	MESH:D002289
30175133	789	792	LBD	Species	
30175133	874	879	lipid	Chemical	MESH:D008055
30175133	913	918	NSCLC	Disease	MESH:D002289
30175133	944	947	PCs	Chemical	MESH:D010713
30175133	952	955	PEs	Chemical	MESH:D010714
30175133	971	976	NSCLC	Disease	MESH:D002289
30175133	977	985	patients	Species	9606
30175133	1008	1011	PCs	Chemical	MESH:D010713
30175133	1016	1019	PEs	Chemical	MESH:D010714
30175133	1053	1072	glycerophospholipid	Chemical	MESH:D020404
30175133	1134	1139	NSCLC	Disease	MESH:D002289
30175133	1220	1223	PCs	Chemical	MESH:D010713
30175133	1228	1231	PEs	Chemical	MESH:D010714
30175133	1290	1295	NSCLC	Disease	MESH:D002289
30175133	1333	1335	PE	Disease	
30175133	1348	1350	PE	Disease	
30175133	1363	1365	PE	Disease	
30175133	1378	1380	PE	Disease	
30175133	1393	1395	PE	Disease	
30175133	1408	1410	PE	Disease	
30175133	1423	1425	PE	Disease	
30175133	1438	1440	PE	Disease	
30175133	1453	1455	PE	Disease	
30175133	1468	1470	PE	Disease	
30175133	1483	1485	PC	Disease	MESH:D015324
30175133	1498	1500	PC	Disease	MESH:D015324
30175133	1517	1519	PC	Disease	MESH:D015324
30175133	1546	1551	NSCLC	Disease	MESH:D002289
30175133	1754	1759	NSCLC	Disease	MESH:D002289
30175133	Association	MESH:D010713	MESH:D002289
30175133	Association	MESH:D008055	MESH:D002289
30175133	Association	MESH:D010714	MESH:D020404
30175133	Association	MESH:D010714	MESH:D002289
30175133	Association	MESH:D020404	MESH:D002289
30175133	Association	MESH:D010713	MESH:D020404

